SCINTIX® autonomous radiotherapy detects and responds to signals emitted from the cancer itself and, for the first time, uses them to deliver immediate treatment for tumors in the lung or bone that may arise from primary or metastatic disease.
SELF-DRIVING RADIOTHERAPY
Cancer is talking. We’re listening.
When radiopharmaceuticals are introduced into the body, cancer cells absorb them and create a biological beacon, which our platform uses to manage motion and autonomously treat solid tumors of any stage of disease.
Targeting Cancer
GOOD NEWS FOR ORGANS. BAD NEWS FOR TUMORS.
Our SCINTIX technology autonomously delivers high doses of radiation to tumors, even those in motion. Live targeting allows for greater impact to the tumor and potentially less dose to surrounding tissues.
ANY STAGE TUMOR
A world where stage is just a number.
Most patients with stage four cancer are not considered candidates for definitive radiotherapy. Our breakthrough SCINTIX therapy creates a new option for patients with lung or bone tumors arising from primary or metastatic cancer.
Combination Treatment
Come at cancer from every angle.
Treating cancer isn’t a one-size-fits-all situation. For many patients, the best treatment plan is a combination of multiple therapies. Adding SCINTIX therapy to chemotherapy, immunotherapy and targeted drugs may potentially improve outcomes.
New payment rates expand patient access to autonomous radiotherapy HAYWARD, Calif., Jan. 22, 2026 – RefleXion Medical, an external-beam theranostic oncology company, today announced that two Medicare Administrator Contractors (MACs) have established payment rates for SCINTIX® autonomous radiotherapy in freestanding centers (FSCs) that appropriately reflect the cost of delivering this advanced therapy. This decision allows […]
Meaningful progress across reimbursement, clinical adoption, and product innovation is helping freestanding cancer centers (FSCs) bring SCINTIX® autonomous radiotherapy to patients in their local communities. This momentum reflects the dedication of our partners in freestanding centers and hospital outpatient departments who are committed to expanding access to advanced cancer care close to home. Payer Progress: Establishing Fair Medicare Reimbursement A […]